Afatinib With or Without Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Safety and Efficacy Results from SWOG S1403

被引：6
|
作者：
Goldberg, S. [1 ]
Redman, M. [2 ]
Lilenbaum, R. [1 ]
Politi, K. [1 ]
Stinchcombe, T. [3 ]
Horn, L. [4 ]
Chen, E. [5 ]
Mashru, S. [6 ]
Gettinger, S. [1 ]
Melnick, M. A. [7 ]
Miao, J. [2 ]
Moon, J. [2 ]
Kelly, K. [8 ]
Gandaram, D. [9 ]
机构：
[1] Yale Univ, Sch Med, New Haven, CT USA
[2] Fred Hutchinson Canc Res Ctr, Swog Stat Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[3] Duke Univ, Durham, NC USA
[4] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[5] Kaiser Permanente, Bellflower, CA USA
[6] Kaiser Permanente, Portland, OR USA
[7] Yale Sch Med, New Haven, CT USA
[8] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA USA
[9] Univ Calif Davis, Ctr Comprehens Canc, Div Hem Oncol, Sacramento, CA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
NSCLC; EGFR;
D O I：
10.1016/j.jtho.2018.08.290
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA10.04
引用
收藏
页码：S343 / S344
页数：2
相关论文
共 50 条
  • [41] Loss of CDKN2A Enhances the Efficacy of Immunotherapy in EGFR-Mutant Non-Small Cell Lung Cancer
    Wang, Simeng
    Lai, Jia-Cheng
    Li, Yu
    Tang, Chengfang
    Lu, Jiajia
    Han, Min
    Ye, Xianjiang
    Jia, Lina
    Cui, Wei
    Yang, Jingyu
    Wu, Chunfu
    Wang, Lihui
    CANCER RESEARCH, 2025, 85 (03) : 585 - 601
  • [42] Inhibition of osteopontin overcomes acquired resistance to afatinib in EGFR-mutant non-small-cell lung cancer
    Zhang, Hongye
    Wang, Ruiyu
    Wang, Mingxia
    Luo, Judong
    Liu, Changmin
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (02) : 754 - 762
  • [43] Transcriptomic Heterogeneity of EGFR-Mutant Non-Small Cell Lung Cancer Evolution Toward Small-Cell Lung Cancer
    Oh, Songji
    Koh, Jaemoon
    Kim, Tae Min
    Kim, Soyeon
    Youk, Jeonghwan
    Kim, Miso
    Keam, Bhumsuk
    Jeon, Yoon Kyung
    Ku, Ja-Lok
    Kim, Dong-Wan
    Chung, Doo Hyun
    Heo, Dae Seog
    CLINICAL CANCER RESEARCH, 2024, 30 (20) : 4729 - 4742
  • [44] A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer
    Yoon, S. H.
    Kim, Y. S.
    Chung, J. H.
    Seol, H. Y.
    Kim, M. H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [45] The Effectiveness of Afatinib as First-Line Treatment in Vietnamese Patients With EGFR-Mutant Non-Small Cell Lung Cancer and Brain Metastases
    Van Pham, Thai
    Vu, Thanh Ha
    Nguyen, Hoa Thai Thi
    Pham, Phuong Cam
    Do, Anh Tu
    Nguyen, Tuan Khoi
    Hoang, Thi Anh Thu
    Le, Tuan Anh
    Vuong, Dinh Thy Hao
    Nguyen, Dac Nhan Tam
    Dang, Van Khiem
    Nguyen, Thi Oanh
    Pham, Van Luan
    Nguyen, Minh Hai
    Vo, Thi Huyen Trang
    Mai, Khoa Trong
    Do, Hung Kien
    Nguyen, Thi Thuy Hang
    Trinh, Le Huy
    Nguyen, Hoang Gia
    Truong, Cong Minh
    Pham, Tran Minh Chau
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024,
  • [46] Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial
    Ahn, M. -J.
    Yang, J.
    Yu, H.
    Saka, H.
    Ramalingam, S.
    Goto, K.
    Kim, S. -W.
    Yang, L.
    Walding, A.
    Oxnard, G. R.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S115 - S115
  • [47] The safety of afatinib for the treatment of non-small cell lung cancer
    Barron, Feliciano
    de la Torre-Vallejo, Martha
    Luz Luna-Palencia, Rosa
    Cardona, Andres F.
    Arrieta, Oscar
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (11) : 1563 - 1572
  • [48] Prognostic impact of pleural effusion in EGFR-mutant non-small cell lung cancer patients without brain metastasis
    Yoshimura, Akihiro
    Yamada, Tadaaki
    Tsuji, Taisuke
    Hamashima, Ryosuke
    Shiotsu, Shinsuke
    Yuba, Tatsuya
    Takumi, Chieko
    Uchino, Junji
    Hiraoka, Noriya
    Takayama, Koichi
    THORACIC CANCER, 2019, 10 (03) : 557 - 563
  • [49] Weight loss in patients on osimertinib for metastatic EGFR-mutant non-small cell lung cancer
    Chen, Lanyi Nora
    Ma, Xin
    Herzberg, Benjamin
    Henick, Brian S.
    Biswas, Anup K.
    Acharyya, Swarnali
    Shu, Catherine A.
    ONCOLOGIST, 2024,
  • [50] Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Non-Small Cell Lung Cancer Cells
    Gao, Wen
    Wang, Michael
    Wang, Li
    Lu, Haibo
    Wu, Shuhong
    Dai, Bingbing
    Ou, Zhishuo
    Zhang, Liang
    Heymach, John V.
    Gold, Kathryn A.
    Minna, John
    Roth, Jack A.
    Hofstetter, Wayne L.
    Swisher, Stephen G.
    Fang, Bingliang
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (09):
12345